GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Ligand Pharmaceuticals LGND · USD

Health Care · US listing · 🇺🇸 United States

Compare

314.15

+2.60%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$268.1m

FY2016FY2025

Net income

$124.5m

FY2016FY2025

Free cash flow

$48.9m

FY2016FY2025

Shareholders' equity

$1.02bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$268.1m$167.1m$131.3m$196.2m$241.5m$163.6m$120.3m$251.5m$141.1m$109.0m
Research and development$81.2m$21.4m$24.5m$36.1m$32.1m$40.5m$55.9m$27.9m$26.9m$21.2m
Operating income$47.2m−$22.6m$11.9m$3.0m$91.8m$37.5m$807.1m$198.0m$68.1m$43.9m
Net income$124.5m−$4.0m$52.2m−$33.4m$57.1m−$3.0m$629.3m$143.3m$12.6m−$1.6m
Diluted earnings per share5.89-0.212.95-1.983.41-0.1836.506.800.59-0.08

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$1.56bn$941.8m$787.2m$762.7m$1.30bn$1.36bn$1.49bn$1.26bn$671.0m$601.6m
Cash and short-term investments$733.5m$256.2m$170.3m$211.9m$341.1m$411.2m$1.07bn$764.6m$201.7m$141.0m
Total liabilities$543.4m$111.3m$86.3m$165.2m$476.4m$652.8m$727.7m$699.9m$252.4m$230.7m
Debt$446.2m$24,000$7,000$76.7m$320.8m$448.9m$639.0m$636.3m$243.4m$242.5m
Shareholders' equity$1.02bn$830.4m$700.9m$597.5m$821.2m$709.5m$767.2m$560.9m$418.6m$370.9m
Shares outstanding21m19m18m17m17m17m17m21m21m21m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$49.4m$97.0m$49.6m$137.8m$78.8m$54.6m−$29.3m$194.1m$93.6m$63.0m
Capital spending−$452,000−$19.6m−$53.8m−$17.9m−$8.8m−$4.5m−$2.6m−$11.9m−$7.2m−$28.3m
Free cash flow$48.9m$77.4m−$4.3m$119.9m$70.0m$50.1m−$31.9m$182.2m$86.4m$34.7m
Dividends paid———−$5.0m−$15.3m−$3.0m−$3.0m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$63.7m$51.7m$59.7m$115.5m$47.6m$45.3m$42.8m$51.8m
Operating income$8.6m$17.4m$20.0m$54.9m$8.4m−$36.2m−$9.6m$3.1m
Net income$48.5m−$13.3m$44.8m$117.3m$4.8m−$42.5m−$31.1m−$7.2m
Diluted earnings per share2.22-0.612.125.550.23-2.01-1.64-0.38
Cash from operations$24.0m$48.0m$45.0m$13.0m$15.0m−$25.0m$28.0m$36.0m
Capital spending———————−$14.0m
Free cash flow———————$22.0m
Total assets$2.19bn$1.53bn$1.56bn$1.48bn$948.6m$905.4m$941.8m$954.9m
Cash and short-term investments$1.36bn$779.4m$733.5m$664.5m$255.3m$208.9m$256.2m$219.6m
Debt$1.13bn$448.0m$447.3m$447.7m$1.1m$883,000$1.3m$1.1m
Shareholders' equity$967.5m$997.3m$1.02bn$950.2m$828.5m$795.5m$830.4m$841.2m

Financial ratios

Data as of 19 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin59.3%3.3%49.0%19.3%38.0%17.6%
Net margin46.4%-2.4%39.7%-17.0%23.7%-1.8%
Return on equity12.2%-0.5%7.4%-5.6%7.0%-0.4%
Return on assets8.0%-0.4%6.6%-4.4%4.4%-0.2%
Free cash flow yield0.8%2.1%2.0%3.1%1.8%1.2%
Revenue growth60.4%27.3%-33.1%-18.8%47.7%36.0%
Earnings growth-3186.6%-107.7%-256.3%-158.4%-2014.2%-100.5%
Current ratio22.23x8.93x14.15x2.67x11.15x5.00x
Debt to equity0.44x0.00x0.00x0.13x0.39x0.64x
Equity ratio65.2%88.2%89.0%78.3%63.3%52.1%
Interest coverage33.71x1.83x98.04x21.02x4.68x1.05x
R&D as a share of sales30.3%12.8%18.7%18.4%13.3%24.8%
Buybacks as a share of market value-11.4%-7.3%-4.7%-0.9%-0.3%3.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue11.0%10.4%14.1%
Operating income149.6%4.7%5.6%
Net income——-7.0%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin5.7%5.2%14.5%70.5%
Net margin27.7%18.3%16.6%66.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings32.1-504.224.2-33.828.2-346.81.812.4143.6-809.7
Price to sales14.912.29.65.86.76.39.37.112.812.2

Market value over time

30 Nov 2016 to 16 Oct 2026, in USD

$1.50bn$6.45bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return73%63%8%-32%54%-6%-22%-0%26%5%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 3 Apr 2007.

FY2007
Paid in the year15.00
  • 6-to-1 reverse split · 19 Nov 2010

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.